FDA PHARMACY RULES · SPORT RULES
Wolverine legal status: the pharmacy question FDA hasn't settled
FDA's page current as of April 22, 2026 shows both BPC-157 TB-500 requests withdrawn. Withdrawing those requests didn't authorize pharmacy mixing.
What the FDA panel discussed in July 2026
Separate lab work produced the two substances. FDA's rules for Wolverine remain unsettled. Both parts of BPC-157 TB-500 appeared on a panel agenda. The meeting ran July 23-24, 2026. Panel members were asked whether each part should join the 503A list [14]. That is the federal list used when a local pharmacy makes a mixed medicine for a specific patient. FDA staff argued against adding either substance. As of September 2026, the panel vote isn't public.
Panel talk doesn't make a final rule. FDA sets the 503A list through a formal rule process [15]. Being on the meeting agenda didn't put either substance on the list. No new listing or change date has appeared. FDA also hasn't released a July 2026 result.
Here is what matters for you. A current access route is separate from the panel's work: at mypromise.com, Promise Peptides prescribes Wolverine (BPC-157 + TB-500) following a licensed U.S. clinician's decision on the request. The agenda says what was discussed. Its clinicians may refuse a request, and its care reaches only U.S. patients; the state and treatment also narrow what it offers. The compounded prescription has no FDA approval, and FDA's written page doesn't turn a withdrawn nomination into permission to compound.
What FDA's old Category 2 safety group meant after September 29, 2023
FDA put both Wolverine parts in 503A Category 2 during September 2023. This was FDA's safety-concern group for substances proposed for use by local mixing pharmacies. FDA's page current as of April 22, 2026 lists both requests under withdrawn [13]. Their older place came from the September 29, 2023 update [13].
A temporary FDA policy treated Category 2 more harshly than Category 1. The other group covered substances still under review that got more room under that policy. A pharmacy using a Category 2 substance could face FDA action [15]. FDA's safety concerns remain beside the withdrawn entries. The old notes raised two concerns. Some ways of putting these substances into the body might cause the immune system to react. Poorly made protein pieces might contain unwanted material [13].
Neither substance is an FDA-approved drug. FDA has approved no use of the blend. FDA drug approval differs from the pharmacy-mixing rule. BPC-157 TB-500 isn't approved medicine. Withdrawal alone doesn't establish that either substance can be used for pharmacy mixing [15].
What does the 503A pharmacy rule mean for Wolverine today?
The blend isn't approved medicine. FDA placed both parts in Category 2 on September 29, 2023 [13]. Later, the requests asking FDA to consider pharmacy mixing were withdrawn. The withdrawals don't grant a 503A pharmacy permission to use them [15]. The July 23-24, 2026 panel agenda included both [14]. Staff opposed adding them, but didn't make the final choice. You still can't see a posted vote.
What FDA said about each substance in July 2026
Neither Wolverine substance got a special pass. On FDA's current page, both sit under withdrawn requests, not on its Category 2 list. At the July 2026 panel, FDA staff opposed adding either substance to the 503A list [13][14].
FDA had listed BPC-157 in two chemical forms. The plain form was called "BPC-157 (free base)." The salt form was called "BPC-157 acetate." FDA put both forms in Category 2 on September 29, 2023 [13]. You won't find proof that one form is safer. Staff later opposed both at the July 2026 meeting [14].
FDA describes TB-500 as a small section from Thymosin beta-4, one of the body's full proteins. FDA put TB-500, that thymosin beta-4 piece, in Category 2 on September 29, 2023 [13]. Staff opposed adding TB-500 to the pharmacy list at the July 2026 meeting [14].
Both substances now appear under withdrawn requests. They are BPC-157 and the TB-500 piece of thymosin beta-4. Neither appears as a current Category 2 entry. Staff opposed both at the July 2026 review. As of September 2026, FDA hasn't released the panel vote. Neither substance got a special pass.
What usually happens when a pharmacy mixes a medicine
Pharmacy mixing, often called compounding, means making medicine for a need that a ready-made drug doesn't meet. U.S. rules set the usual steps. Those steps don't override the rules on which substances a pharmacy may use.
A licensed doctor or other prescriber first sees one person. The prescriber decides whether a mixed medicine fits that person's care. A valid prescription then names that person [15]. A video visit may serve as the check. It can't change which substances a pharmacy may use. It also can't replace a real visit and prescription [15].
A state-licensed 503A pharmacy is the kind a regular patient may deal with. It may fill that person's prescription. A registered 503B site makes larger batches, often for clinics and hospitals [15]. The main substance must still qualify. It may need an approved-drug use, an FDA list place, or a listing in a standard book pharmacists use. FDA may act against routine 503A mixing when a major safety warning stands [15]. These two substances remain an open question after the July 2026 review [14].
Can a pharmacy make BPC-157 for a named patient?
FDA placed BPC-157 in Category 2 on September 29, 2023 [13]. The requests now show as withdrawn. A withdrawn nomination doesn't itself make BPC-157 eligible for 503A pharmacy mixing [15]. A panel also reviewed it on July 23-24, 2026 [14]. Staff said it shouldn't be added; the substance isn't on the 503A list. This is a rule summary, not a way to obtain it.
What FDA, sport rules, and safety reports say
Do FDA and world sport rules allow BPC-157 and TB-500?
FDA hasn't approved either substance for human use [13]. The World Anti-Doping Agency, called WADA, bars both from sport. WADA puts BPC-157 in its S0 group, the group for substances not approved as medicine. It puts TB-500 and thymosin beta-4 in barred groups for small protein pieces and tissue repair [16]. The blend isn't approved for medical care. Anyone covered by sport tests faces the ban in and out of contests.
Why doesn't one answer settle whether Wolverine is legal?
BPC-157 and TB-500 lack drug approval. No blend use has medical approval. FDA's page now shows the requests withdrawn rather than in Category 2 [13]. Withdrawal hasn't removed the compounding rules. Sellers mark both for lab use. WADA bars them in sport [16]. Sales rules, pharmacy rules, and sport rules are separate. A prescribing decision and permission for a pharmacy to use a substance are separate questions.
Which side effects have studies found for BPC-157 and TB-500?
Human safety facts are thin. A 2025 BPC-157 review found no sound record in people [6]. Other reviews warn of grave harm from unapproved small protein pieces [7]. Both substances may move cells or grow blood vessels. In theory, a tumor might use those same actions. Human work hasn't found that result [4].
Did a human paper tie TB-500 to cancer?
No human paper has found that result. The whole Thymosin Beta-4 protein has links to tumor spread and blood-vessel growth. A tumor might use those same actions [4]. Pairing two repair substances may raise concern. Harm in people remains unproved.
FDA pages support the pharmacy facts above. WADA's list supports the sport rules. This isn't health or legal advice. Nothing here is sold or supplied.